"defining biomolecular characterization"
Dr. White received the B.S. and M.S degrees in chemistry from Jackson State University in Jackson, MS and his Ph.D. in Analytical Chemistry from the University of North Carolina at Chapel Hill, NC where he specialized in mass spectrometry. He began his career as a forensic toxicologist with the University of Mississippi Med Center/MS State Crime Laboratory. Following the completion of his Ph.D., he joined RJ Reynolds Tobacco Co. until 1998 when Dr. White accepted a position with Large Scale Biology Corporation (LSBC) as a Senior Scientist. There he established The Analytical Center of Excellence and was subsequently promoted to Director of Advanced Analytical Resources and Quality Control for LSBC's Non-Hodgkin’s Lymphoma (NHL) cancer vaccines program, the company's first clinical product candidate. In 2002, he was appointed Vice President, Advanced Analytical Sciences. In addition to his role as Vice President of Advance Analytical Sciences for LSBC and Predictive Diagnostics, Inc. (PDI). From July 2007 until 2008 Dr. White served as Vice President, Analytical and Pharmaceutical Sciences for Integrated Biomolecule Corporation. Dr. White founded MDx Laboratory, Inc. in 2008 drawing upon his experience to focus his expertise in the field of biomolecular characterization. He later accepted a position as Director of Quality Labs with Caliber Biotherapeutics and served as Director of R&D/Quality Labs until the facility was acquired by iBio where he served as VP of R&D. In addition to his career in the private sector Dr. White served and retired from the US Army Reserve after over 34 years achieving the rank of Lieutenant Colonel.
Dr. White’s career in biotechnology and biopharmaceutical research and development spans over 40 years and includes technical and executive leadership roles.
Mr. Ferreira received his B.S in Natural Science from SUNY Polytechnic. He began his career in Research and Development with the Masonic Medical Research Laboratory studying DNA degradation products. In subsequent years Mr. Ferreira expanded his expertise in the recovery and purification of biomolecules as well as the synthesis of biopolymers including peptides and DNA employed by BioRad Laboratories and Pharmacia LKB. In 1991 he founded Bänziger Systems Inc. a company that provided cGMP compliance, validation and regulatory support services to drug and biologics manufacturing firms in the U.S. Europe and Canada. In 2010, Mr. Ferreira accepted a position with the firm GCON, a startup developing a novel flexible mobile clean room technology and Caliber Biotherapeutics a firm owned by GCON engaged in a proof-of-concept project funded by DARPA. In his role with GCON and Caliber Mr. Ferreira guided the development of the firm’s quality systems program and the design/build of a new manufacturing facility for the production of a plant expressed H1N1 Influenza vaccine supporting DARPA’s Blue Angel Project. Following the successful completion of the projects Mr. Ferreira took the positon of Senior Vice President of Quality for Kalon Biotherapeutics, LLC a Texas A&M owned company. In this role, his responsibilities included designing and implementing the firms Quality Systems program as well as serving on the executive leadership team tasked with business development and expansion. The team successfully secured the company’s position as one of three biodefense centers in the U.S., the Center for Innovation and Advanced Development and Manufacturing (CIADM. Prior to joining MDx BioAnalytical Laboratory, Mr. Ferreira served as Director of Blinn Colleges Therapeutics Manufacturing Program where he completed the implementation of an A.A.S degree program in Therapeutics Manufacturing designed to build a local workforce capable of supporting the Bryan College Station Texas emerging biopharmaceutical industry. Prior to entering college, Mr. Ferreira served seven years in the United States Marine corp. attaining the rank of Sergeant before receiving his Honorable Discharge in 1980.
Mr. Ferreira’s career in biotechnology and biopharmaceutical research and development spans over 30 years and includes technical and executive leadership roles.